| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PX, England [B. M. B., M. J., M. H. B., I. E. S.], and The University of Edinburgh, Medical Oncology Unit, The Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland [J. F. S.]
A sensitive method, based on gas chromatography using a phosphorus-specific flame photometric detector, has been developed for quantifying N,N'-di-(2-chloroethyl)phosphorodiamidic acid (isophosphoramide mustard), the putative active metabolite of isophosphamide, in human plasma. Phosphoramide mustard was used as internal standard, and the two compounds were converted into separable trimethyl derivatives by reaction with methyl iodide in the presence of silver oxide. The chemistry of the derivatization process has been elucidated using gas chromatography-electron impact mass spectrometry and selected ion monitoring. Levels of isophosphamide and of isophosphoramide mustard were measured in the plasma of patients receiving isophosphamide (2 g/sq m). Peak plasma levels of isophosphoramide mustard of 18.6 to 30.3 nmol/ml occurred at 2 to 4 hr, and levels were still appreciable (6.3 to 11.3 nmol/ml) at 24 hr.
1 This investigation was supported by a grant to the Institute of Cancer Research from the Medical Research Council (Grant G973/786).
2 2-(2-Chloroethyl)amino-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide.
3 Gordon Hamilton Fairley Research Training Fellow.
4 To whom requests for reprints should be addressed.
Received 3/18/80. Accepted 8/27/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |